Switching from methylphenidate-immediate release (MPH-IR) to methylphenidate-OROS (OROS-MPH): A multi-center, open-label study in Korea

Clinical Psychopharmacology and Neuroscience

Volumn 9, Issue 1, 2011, Pages 29-35

  Kim, Bung Nyun ^a   Kim, Ye Ni ^b   Cheong, Un Sun ^c   Kim, Jae Won ^a   Hwang, Jun Won ^d   Shin, Min Sup ^a   Cho, Soo Churl ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Eulji University   (South Korea)

Author keywords

Attention deficit hyperactive disorder; Methylphenidate IR; OROS MPH; Switching

Indexed keywords

METHYLPHENIDATE;

ABDOMINAL PAIN; ANOREXIA; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; KOREA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; TIC;

EID: 79955758628     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: 10.9758/cpn.2011.9.1.29     Document Type: Article

References (21)

1. Canino G, Shrout PE, Rubio-Stipec M, Bird HR, Bravo M, Ramirez R, et al. The DSM-IV rates of child and adolescent disorders in Puerto Rico: prevalence, correlates, service use, and the effects of impairment. Arch Gen Psychiatry 2004;61:85-93.
2. Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 2003;42:1203-1211.
3. Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001;107:E43.
4. Cho SC, Shin YO. Prevalence of disruptive behavior disorders. J Korean Acad Child Adolesc Psychiatry 1994;5:141-149.
5. Kim BN. Community based study for characteristics of children with subthreshold attention deficit hyperactivity disorder. J Korean Neuropsychiatric Association 2002;41:110-122.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American psychiatric Association; 1994.
7. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998;279:1100-1107.
8. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:50-62.
9. Kim BN, Yoo HI, Kang HW, Shin DW, Ahn DH. The Korean practice parameter for the treatment of ADHD. J Korean Acad Child Adolesc Psychiatry 2007;18:10-31.
10. Hwang JW, Kim BN, Cho SC. Compliance study of methylph-enidate in the treatment of ADHD. J Korean Acad Child Adolesc Psychiatry 2004;15:160-167.
11. Hinshaw SP, Melnick SM. Peer relationships in children with attention-deficit hyperactivity disorder with and without comorbid aggression. Dev Psychopathol 1995;7:627-647.
12. Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36:754-763.
13. Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, et al. Symptom control in children and adolescents with attention-deficit/ hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 2005;14:297-304.
14. Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005;14:305-309.
15. Barkley RA, Cunningham CE. The effects of methylphenidate on the mother-child interactions of hyperactive children. Arch Gen Psychiatry 1979;36:201-208.
16. Barkley RA, Karlsson J, Strzelecki E, Murphy JV. Effects of age and Ritalin dosage on the mother-child interactions of hyperactive children. J Consult Clin Psychol 1984;52:750-758.
17. Pelham WE, Bender ME, Caddell J, Booth S, Moorer SH. Methylphenidate and children with attention deficit disorder. Dose effects on classroom academic and social behavior. Arch Gen Psychiatry 1985;42:948-952.
18. Pelham WE Jr, McBurnett K, Harper GW, Milich R, Murphy DA, Clinton J, et al. Methylphenidate and baseball playing in ADHD children: who's on first? J Consult Clin Psychol 1990;58:130-133.
19. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56:1073-1086.
20. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:E105.
21. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-211.